# Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts

> **NCT05799157** · PHASE2 · COMPLETED · sponsor: **Veradermics, Inc.** · enrollment: 153 (actual)

## Conditions studied

- Verruca Vulgaris
- Warts
- Common Wart

## Interventions

- **DRUG:** VDMN-21 Patch Low Dose
- **DRUG:** VDMN-21 Patch High Dose
- **DRUG:** Vehicle Patch

## Key facts

- **NCT ID:** NCT05799157
- **Lead sponsor:** Veradermics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-28
- **Primary completion:** 2025-02-25
- **Final completion:** 2025-02-25
- **Target enrollment:** 153 (ACTUAL)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05799157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05799157, "Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05799157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*